"The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.
HER2 is a protein involved in normal cell growth. It is foun"...
DOSAGE AND ADMINISTRATION
When possible, to reduce the risk of developing cardiotoxicity in patients receiving ELLENCE after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, ELLENCE-based therapy should be delayed until the other agents have cleared from the circulation [see WARNINGS AND PRECAUTIONS].
Administer ELLENCE Injection by intravenous infusion. Give ELLENCE in repeated 3-to 4-week cycles. The total dose of ELLENCE may be given on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle. The recommended dosages of ELLENCE are as follows:
The recommended dose of ELLENCE is 100 to 120 mg/m². The following regimens are recommended:
|CEF-120:||Cyclophosphamide||75 mg/m² PO D 1-14|
|ELLENCE||60 mg/m² IV D 1, 8|
|5-Fluorouracil||500 mg/m² IV D 1, 8|
|Repeated every 28 days for 6 cycles|
All drugs administered intravenously on Day 1 and repeated every 21 days for 6 cycles
ELLENCE dosage adjustments for hematologic and non-hematologic toxicities within a cycle of treatment, is based on nadir platelet counts < 50,000/mm³, absolute neutrophil counts (ANC) < 250/mm³, neutropenic fever, or Grades 3/4 nonhematologic toxicity. Reduce ELLENCE Day 1 dose in subsequent cycles to 75% of the Day 1 dose given in the current cycle. Delay Day 1 chemotherapy in subsequent courses of treatment until platelet counts are ≥ 100,000/mm³, ANC ≥ 1500/mm³, and nonhematologic toxicities have recovered to ≤ Grade 1.
Bone Marrow Dysfunction
Consider administering a lower starting dose (75-90 mg/m²) for heavily pretreated patients, patients with pre-existing bone marrow depression, or in the presence of neoplastic bone marrow infiltration [see WARNINGS AND PRECAUTIONS]. For patients receiving a divided dose of ELLENCE (Day 1 and Day 8), the Day 8 dose should be 75% of Day 1 if platelet counts are 75,000-100,000/mm³ and ANC is 1000 to 1499/mm³. If Day 8 platelet counts are < 75,000/mm³, ANC < 1000/mm³, or Grades 3/4 nonhematologic toxicity has occurred, omit the Day 8 dose.
Recommendations regarding use of ELLENCE in patients with hepatic impairment are not available because patients with hepatic abnormalities were not included in the adjuvant trials [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY]. In patients with elevated serum AST or serum total bilirubin concentrations, the following dose reductions are recommended:
- Bilirubin 1.2 to 3 mg/dL or AST 2 to 4 times upper limit of normal ½ of recommended starting dose
- Bilirubin > 3 mg/dL or AST > 4 times upper limit of normal 1/4 of recommended starting dose
While no specific dose recommendation can be made based on the limited available data in patients with renal impairment, consider lower doses in patients with severe renal impairment (serum creatinine > 5 mg/dL) [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY].
Preparation And Administration Precautions
Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15-25°C).
Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Procedures for proper handling and disposal of anticancer drugs should be used when handling and preparing ELLENCE. Several guidelines on this subject have been published.1-4[see REFERENCES].
Take the following protective measures when handling ELLENCE:
- Train personnel in appropriate techniques for reconstitution and handling.
- Exclude pregnant staff from working with this drug.
- Wear protective clothing: goggles, gowns, and disposable gloves and masks when handling ELLENCE.
- Define a designated area for syringe preparation (preferably under a laminar flow system), with the work surface protected by disposable, plastic-backed, absorbent paper.
- Place all items used for reconstitution, administration, or cleaning (including gloves) in high-risk, waste-disposal bags for high temperature incineration.
- Treat spillage or leakage with dilute sodium hypochlorite (1% available chlorine) solution, preferably by soaking, and then water. Place all contaminated and cleaning materials in high-risk, waste-disposal bags for incineration. Treat accidental contact with the skin or eyes immediately by copious lavage with water, or soap and water, or sodium bicarbonate solution. However, do not abrade the skin by using a scrub brush. Seek medical attention. Always wash hands after removing gloves.
Avoid prolonged contact with any solution of an alkaline pH as it will result in hydrolysis of the drug. Do not mix ELLENCE with heparin or fluorouracil due to chemical incompatibility that may lead to precipitation.
ELLENCE can be used in combination with other antitumor agents, but do not mix with other drugs in the same syringe.
Preparation of Infusion Solution
Administer ELLENCE into the tubing of a freely flowing intravenous infusion (0.9% sodium chloride or 5% glucose solution). Patients receiving initial therapy at the recommended starting doses of 100-120 mg/m² should generally have ELLENCE infused over 15-20 minutes. For patients who require lower ELLENCE starting doses due to organ dysfunction or who require modification of ELLENCE doses during therapy, the ELLENCE infusion time may be proportionally decreased, but should not be less than 3 minutes. This technique is intended to minimize the risk of thrombosis or perivenous extravasation, which could lead to severe cellulitis, vesication, or tissue necrosis. A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration. Venous sclerosis may result from injection into small vessels or repeated injections into the same vein [see WARNINGS AND PRECAUTIONS]. Use ELLENCE within 24 hours of first penetration of the rubber stopper. Discard any unused solution.
Dosage Forms And Strengths
ELLENCE is provided in polypropylene single-use CYTOSAFE™ vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use solution in the following sizes: 50 mg/25 mL and 200 mg/100 mL.
Storage And Handling
ELLENCE Injection is available in polypropylene single-use CYTOSAFE™ vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use solution in the following strengths:
50 mg/25 mL single-use vial NDC
200 mg/100 mL single-use vial NDC 0009-5093-01
Store refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light.
Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15-25°C). Solution for injection should be used within 24 hours after removal from refrigeration.
1. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
2. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html.
3. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:1172-1193.
4. Polovich, M., White, J. M. & Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.
Distributed by: Pharmacia & Upjohn Co, Division of Pfizer Inc., New York, NY, NY 10017. Revised: December 2014
Last reviewed on RxList: 12/30/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Ellence Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.